Please try another search
For the fiscal year ended 31 December 2019, Bbi Life Sciences Corp revenues increased 21% to RMB703.8M. Net income increased 11% to RMB88.1M. Revenues reflect DNA synthesis products segment increase of 23% to RMB267.1M, Genetic engineering services segment increase of 29% to RMB162.9M, PRC segment increase of 26% to RMB555.9M, Overseas segment increase of 6% to RMB147.9M.
Period Ending: | Dec 31, 2019 | Jun 30, 2019 | Dec 31, 2018 | Jun 30, 2018 |
---|---|---|---|---|
Total Revenue | 381.32 | 322.45 | 313.15 | 268.45 |
Gross Profit | 179.19 | 169.48 | 146.06 | 137.23 |
Operating Income | 49.92 | 51.4 | 41.14 | 42.86 |
Net Income | 41.65 | 46.45 | 41.37 | 37.73 |
Period Ending: | Dec 31, 2019 | Jun 30, 2019 | Dec 31, 2018 | Jun 30, 2018 |
---|---|---|---|---|
Total Assets | 1245.83 | 1134.37 | 1018.01 | 942.31 |
Total Liabilities | 388.14 | 324.35 | 243.35 | 215.84 |
Total Equity | 857.69 | 810.01 | 774.66 | 726.47 |
Period Ending: | Dec 31, 2019 | Jun 30, 2019 | Dec 31, 2018 | Jun 30, 2018 |
---|---|---|---|---|
Period Length: | 12 Months | 6 Months | 12 Months | 6 Months |
Cash From Operating Activities | 134.38 | 24.55 | 116.36 | -0.11 |
Cash From Investing Activities | -250.66 | -76.62 | -162.18 | -72.42 |
Cash From Financing Activities | 38.94 | 70.08 | 1.37 | 1.15 |
Net Change in Cash | -74.15 | 17.39 | -40.53 | -71.36 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review